A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Not yet recruitingOBSERVATIONAL
Enrollment

223

Participants

Timeline

Start Date

November 4, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

November 1, 2032

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DRUG

Current standard of care treatment options

According to the product label

Trial Locations (11)

11203

Local Institution - 0039, Brooklyn

24105

Local Institution - 0041, Kiel

34362

Local Institution - 0036, Haifa

44124

Local Institution - 0040, Ferrara

55131

Local Institution - 0043, Mainz

92128-2551

Local Institution - 0035, San Diego

48109-5000

Local Institution - 0034, Ann Arbor

27710-1000

Local Institution - 0037, Durham

T4000AXL

Local Institution - 0029, San Miguel de Tucumán

05403-000

Local Institution - 0042, São Paulo

J1G 2E8

Local Institution - 0038, Sherbrooke

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY